FitLife Brands, Inc. — 2016 Q1 Form 10-Q Summary
Business context and reporting period
FitLife Brands, Inc. is a nutritional-supplement company marketing NDS, PMD, SirenLabs, CoreActive, Metis Nutrition, iSatori, CT Fletcher, BioGenetic Laboratories and Energize brands. Products are sold primarily through GNC, specialty, mass-market and online channels. The iSatori merger became effective October 1, 2015, making this the first comparable quarter including a full period of iSatori operations.
The filing covers the three months ended March 31, 2016. The interim consolidated financial statements are unaudited and include normal recurring adjustments; management states that quarterly results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | $7.883 million | $3.842 million | 105.2% increase |
| Gross profit | $3.618 million | $1.576 million | 129.7% increase |
| Gross margin | 45.9% | 41.0% | Improved |
| Operating income (loss) | $918,018 | $(15,616) | Improved |
| Operating margin | 11.6% | (0.4%) | Improved |
| Net income (loss) | $814,154 | $(42,263) | Returned to profitability |
| Diluted earnings (loss) per share | $0.07 | $(0.01) | Improved |
| Cash flow from operations | $(1.203) million | $407,391 | Declined |
Management attributes revenue growth to continued improvement in GNC sales and $2.620 million of revenue from iSatori products. Excluding iSatori, revenue increased approximately 37.0% to $5.3 million. Gross-margin improvement was attributed to cost-cutting initiatives.
Cash declined from $1.533 million at December 31, 2015 to $707,599 at March 31, 2016. Operating cash use primarily reflected a $2.533 million increase in accounts receivable, partially offset by a $1.254 million reduction in inventory. Investing activities used $7,745, while financing activities provided $385,834, including $520,000 of long-term debt proceeds and $134,166 of note repayments.
Total assets were $17.656 million and total liabilities were $6.672 million at March 31, 2016. Current assets were $9.874 million versus current liabilities of $5.892 million, implying a current ratio of approximately 1.67. Accounts receivable rose to $5.218 million from $2.685 million at year-end 2015, while inventory fell to $3.537 million from $4.790 million.
Total debt and advances were $3.370 million, including a $2.010 million revolving line of credit, $1.310 million term loan and $49,546 of equipment-related notes. The revolving line matured May 15, 2016. Management stated that existing cash and anticipated operating cash flow were expected to provide liquidity for the next 12 months.
Material changes versus the prior comparable period
- Revenue more than doubled, largely because of the iSatori acquisition and continued GNC sales growth.
- Gross margin increased to 45.9% from 41.0%, and the company moved from an operating loss and net loss to operating and net income.
- General and administrative expense increased 47.9% to $1.379 million, principally because of iSatori; excluding iSatori, management reported a 24.8% decrease.
- Selling and marketing expense increased to $1.197 million from $604,000, with approximately $600,000 attributed to iSatori.
- Depreciation and amortization increased to $124,756 from $55,277.
- Operating cash flow changed from a $407,391 inflow to a $1.203 million outflow, primarily because of higher receivables and working-capital requirements.
- Shares outstanding increased materially following the iSatori merger. The company issued 2,315,644 shares to former iSatori shareholders and reported 10,368,112 shares outstanding at March 31, 2016.
- The company changed its treatment of vendor-funded GNC discounts for indirect distribution, estimating discounts at shipment and recording them as a reduction of revenue. Management stated that the change reduced revenue and selling expense but did not affect operating or net income.
Guidance, outlook, risks and unusual items
Management expects continued growth from new and reformulated products, broader GNC distribution, international expansion and iSatori products. It also expects selling and marketing expense to rise more slowly than revenue and anticipates lower general and administrative expense as a percentage of revenue as iSatori integration progresses. No quantified financial guidance was provided.
NDS was not in compliance with certain financial covenants under its U.S. Bank term loan and revolving line of credit as of March 31, 2016. The company subsequently received a waiver for the quarter. Management warned that future noncompliance could result in acceleration of amounts owed and materially harm financial condition.
The company paid a $90,000 settlement on April 18, 2016 relating to an alleged California Proposition 65 labeling matter. A separate lawsuit involving Testofen-related marketing claims was stayed pending an appeal. Met-Rx has filed counterclaims involving the METIS NUTRITION trademark; the company disputes the allegations.
Material risks include reliance on key customers and suppliers, competition, market demand, product performance, employee retention, regulatory and labeling matters, litigation, covenant compliance, working-capital needs and the ability to collect increased accounts receivable. The company had approximately $22.4 million of federal net operating loss carryforwards, but a substantial valuation allowance remained against related tax benefits. No impairment of long-lived assets was recorded.
Management reported effective disclosure controls and internal control over financial reporting as of the period end. The filing contains an apparent date inconsistency in the internal-control discussion, which refers to March 31, 2015 rather than March 31, 2016.
Important facts for investors to verify
- Whether the company can convert the large increase in accounts receivable into cash and sustain positive operating cash flow.
- Whether the U.S. Bank covenant waiver and the May 15, 2016 revolving-credit maturity were successfully resolved after filing.
- The extent to which revenue growth and margin expansion are attributable to iSatori versus organic NDS growth.
- The integration costs, operating synergies and continuing dilution associated with the iSatori merger, options and warrants.
- Exposure to GNC and other major customers, including the effect of vendor-funded discount estimates on reported revenue.
- The potential financial or operational impact of the Met-Rx trademark litigation and the stayed Testofen litigation.
- The availability and utilization limits of federal and state net operating loss carryforwards, including possible Section 382 restrictions.